Anti-Tenascin C Antibody Development

Based on our advanced technology and years of experience, Creative Biolabs has become a specialized manufacturer in different forms of antibodies, such as bispecific antibodies, therapeutic antibodies, antibody-drug conjugates (ADC) and single domain antibodies. At present, we are available to supply antibodies development services against tenascin C protein that can be applicated in your various research uses.

Tenascin C

In addition to soluble factors, the extracellular matrix (ECM) also plays a vital role in normal vasculogenesis and in the pathological angiogenesis of many disease states. Tenascin C is one of large modular ECM proteins that exhibits a restricted and low expression in normal tissue but highly expressed during organogenesis accompanying cell proliferation and migration, epithelial-mesenchymal transition (EMT). It is the founding member of the tenascin family with four members, tenascin C, R, W and tenascin X. Each tenascin C subunit is composed of four domains: a cysteine-rich N-terminus tenascin assembly domain (TA), a epidermal growth factor (EGF)-like repeats (EGF-L), a region of up to 17 fibronectin type III-like (FNIII) repeats (9 of these, named A1/2/3/4, B, AD2, AD1, C, and D, are susceptible to alternative splicing), and a C-terminal fibrinogen-like globe (FBG). Tenascin C splice variants represent a group of non-internalizing antigens, which can be efficiently targeted by cognate monoclonal antibodies.

Fig.1 The domain structure of tenascin C. (Trebaul, 2007)

The increased deposition of tenascin C has been reported in the tumor stroma of most epithelial malignancies arising. For example, in the breast, uterus, ovary, pancreas, colon, stomach and so forth. Deposited tenascin C in the cancer stroma modulates the cell behaviors in tumor growth, epithelial-mesenchymal transition, cell proliferation, and migration by interacting with several ECM molecules and cell surface receptors that are mediated through integrin.

Anti-tenascin C Antibody

Because of their selective expression at the tumor site, stability and abundance, components of the modified tumor ECM, such as splice isoforms of tenascin C, fibronectin, and certain collagens, are attractive targets for pharmaceutical applications. For instance, ADC products, based on the fully-human F16 antibody specific to the alternatively spliced A1 domain of tenascin C, has exhibited promising biodistribution results in mouse models of cancer and in patients. Additionally, the binding properties and the tumor targeting performance of the F16 antibody could be improved by the substitution of an asparagine residue in the VL domain with glutamine. Drugs released in the tumor extracellular space may diffuse and subsequently internalize into tumor cells, endothelial cells and in tumor-resident leukocytes.

Fig.2 Schematic representation of IgG(F16)-MMAE. (Dal Corso, 2017)

Equipped with significant knowledge and rich experiences in antibody-related services, Creative Biolabs offers a number of advanced strategies to prepare the most comprehensive antibodies against tenascin C with high purity and affinity. We are glad to share our experience and help our customers in antibody development against tenascin C protein. Please feel free to contact us for more information and a detailed quote.

References

1. Trebaul, A.; et al. Regulation of fibroblast migration by tenascin-C. Biochemical Society Transactions. 2007, 35(4), 695-7.
2. Dal Corso, A.; et al. A non-internalizing antibody-drug conjugate based on an anthracycline payload displays potent therapeutic activity in vivo. Journal of Controlled Release. 2017, 264, 211-218.

For Research Use Only. NOT FOR CLINICAL USE.